增强针对慢性肾病的内源性防御能力。 - Suppr

Suppr

超能文献

Ramping up endogenous defences against chronic kidney disease.

作者信息

Eddy Allison A

出版信息

Nephrol Dial Transplant. 2006 May;21(5):1174-7. doi: 10.1093/ndt/gfl102. Epub 2006 Mar 30.

DOI:10.1093/ndt/gfl102

PMID:16574685

Abstract

摘要

相似文献

Ramping up endogenous defences against chronic kidney disease.

Nephrol Dial Transplant. 2006 May;21(5):1174-7. doi: 10.1093/ndt/gfl102. Epub 2006 Mar 30.

Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.

J Nephrol. 2004 Jul-Aug;17(4):496-503.

The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function.

J Nephrol. 2003 Mar-Apr;16(2):179-85.

[BMP-7 (Bone morphogenetic protein-7): a future treatment for chronic renal failure?].

Rev Med Suisse. 2005 Feb 23;1(8):568-70, 572-3.

Balance between bone morphogenetic proteins and their antagonists in kidney injury.

Ther Apher Dial. 2007 Oct;11 Suppl 1:S38-43. doi: 10.1111/j.1744-9987.2007.00520.x.

BMP7 signaling in renal development and disease.

Trends Mol Med. 2005 Nov;11(11):512-8. doi: 10.1016/j.molmed.2005.09.007. Epub 2005 Oct 10.

Bone morphogenic protein-7 and the kidney: current concepts and open questions.

Nephrol Dial Transplant. 2006 Mar;21(3):568-73. doi: 10.1093/ndt/gfk010. Epub 2005 Dec 22.

Vascular calcification and uremia: what do we know?

Am J Nephrol. 2008;28(2):339-46. doi: 10.1159/000111827. Epub 2007 Nov 29.

The effects of rapamycin in the progression of renal fibrosis.

Transplant Proc. 2007 Mar;39(2):457-9. doi: 10.1016/j.transproceed.2007.01.031.

Reversal of renal disease: is it enough to inhibit the action of angiotensin II?

Cell Death Differ. 2007 Jul;14(7):1343-9. doi: 10.1038/sj.cdd.4402143. Epub 2007 Mar 30.

引用本文的文献

Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome.

J Clin Invest. 2010 Mar;120(3):768-77. doi: 10.1172/JCI39569. Epub 2010 Feb 8.

Late kidney allograft loss: what we know about it, and what we can do about it.

Clin J Am Soc Nephrol. 2008 Mar;3 Suppl 2(Suppl 2):S56-67. doi: 10.2215/CJN.03040707.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Ramping up endogenous defences against chronic kidney disease.

Nephrol Dial Transplant. 2006 May;21(5):1174-7. doi: 10.1093/ndt/gfl102. Epub 2006 Mar 30.

Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.

J Nephrol. 2004 Jul-Aug;17(4):496-503.

The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function.

J Nephrol. 2003 Mar-Apr;16(2):179-85.

[BMP-7 (Bone morphogenetic protein-7): a future treatment for chronic renal failure?].

Rev Med Suisse. 2005 Feb 23;1(8):568-70, 572-3.

Balance between bone morphogenetic proteins and their antagonists in kidney injury.

Ther Apher Dial. 2007 Oct;11 Suppl 1:S38-43. doi: 10.1111/j.1744-9987.2007.00520.x.

BMP7 signaling in renal development and disease.

Trends Mol Med. 2005 Nov;11(11):512-8. doi: 10.1016/j.molmed.2005.09.007. Epub 2005 Oct 10.

Bone morphogenic protein-7 and the kidney: current concepts and open questions.

Nephrol Dial Transplant. 2006 Mar;21(3):568-73. doi: 10.1093/ndt/gfk010. Epub 2005 Dec 22.

Vascular calcification and uremia: what do we know?

Am J Nephrol. 2008;28(2):339-46. doi: 10.1159/000111827. Epub 2007 Nov 29.

The effects of rapamycin in the progression of renal fibrosis.

Transplant Proc. 2007 Mar;39(2):457-9. doi: 10.1016/j.transproceed.2007.01.031.

Reversal of renal disease: is it enough to inhibit the action of angiotensin II?

Cell Death Differ. 2007 Jul;14(7):1343-9. doi: 10.1038/sj.cdd.4402143. Epub 2007 Mar 30.

引用本文的文献

Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome.

J Clin Invest. 2010 Mar;120(3):768-77. doi: 10.1172/JCI39569. Epub 2010 Feb 8.

Late kidney allograft loss: what we know about it, and what we can do about it.

Clin J Am Soc Nephrol. 2008 Mar;3 Suppl 2(Suppl 2):S56-67. doi: 10.2215/CJN.03040707.